Market Overview

Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018

Share:

CRANBURY, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2018.

The call will be led by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 5887047.

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.  

A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on August 7, 2018. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 5887047.

About Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable genetic mutations. The lead biologics program in the Amicus pipeline is AT-GAA, a novel, late-stage treatment for Pompe disease. Amicus is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com.

CONTACTS:

Investors/Media:
Amicus Therapeutics
Andrew Faughnan
Associate Director, Investor Relations
afaughnan@amicusrx.com  
(609) 662-3809

Media:
Pure Communications
Jennifer Paganelli
jpaganelli@purecommunications.com 
(347) 658-8290

FOLD–G

Primary Logo

View Comments and Join the Discussion!